Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 10/20 | 0.52 |
| ▸ | MMP9 | P14780 | 10/20 | 0.52 |
| ▸ | MMP8 | P22894 | 10/20 | 0.52 |
| ▸ | MMP13 | P45452 | 9/20 | 0.52 |
| ▸ | BMP1 | P13497 | 8/20 | 0.51 |
| ▸ | MMP3 | P08254 | 3/20 | 0.47 |
| ▸ | MMP1 | P03956 | 2/20 | 0.47 |
| ▸ | MMP14 | P50281 | 2/20 | 0.47 |
| ▸ | MMP16 | P51512 | 2/20 | 0.47 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856468 | 1.00 | MMP2 (0.52) | MMP2MMP9MMP8MMP13BMP1 | |
| SCHEMBL4071224 | 0.93 | MMP2 (0.58) | MMP2MMP9MMP8MMP13BMP1 | |
| SCHEMBL4071230 | 0.93 | MMP2 (0.58) | MMP2MMP9MMP8MMP13BMP1 | |
| SCHEMBL2860365 | 0.93 | BMP1 (0.58) | MMP2MMP9MMP8MMP13BMP1 | |
| SCHEMBL2860368 | 0.93 | BMP1 (0.58) | MMP2MMP9MMP8MMP13BMP1 | |
| SCHEMBL2859275 | 0.92 | MMP2 (0.57) | MMP2MMP9MMP8MMP13BMP1 | |
| SCHEMBL2859278 | 0.92 | MMP2 (0.57) | MMP2MMP9MMP8MMP13BMP1 | |
| SCHEMBL2859273 | 0.92 | MMP2 (0.54) | MMP2MMP9MMP8MMP13BMP1 | |
| SCHEMBL2859266 | 0.92 | MMP2 (0.54) | MMP2MMP9MMP8MMP13BMP1 | |
| SCHEMBL2854087 | 0.89 | MMP2 (0.49) | MMP2MMP9MMP8MMP13BMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2085379-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | Novartis AG (CH) | 2009-08-05 | — | — | EP | claimed |
| US-7138432-B1 | Arylsulfonamido-substituted hydroxamic acid derivatives | NOVARTIS AG (CH) | 2006-11-21 | — | — | US | claimed |
| CN-1215055-C | Arylsulfonylamino-substituted hydroxamic acid derivatives | NOVARTIS AG (CH) | 2005-08-17 | — | — | CN | claimed |
| CN-1368958-A | Arylsulfonamido-substituted hydroxamic acid derivatives | NOVARTIS AG (CH) | 2002-09-11 | — | — | CN | claimed |
| EP-1202961-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | Novartis AG (CH) | 2002-05-08 | — | — | EP | claimed |
| WO-2001010827-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2001-02-15 | — | — | WO | claimed |
| EP-1202961-B1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2010-01-20 | — | — | EP | disclosed |
| EP-2085379-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | Novartis AG (CH) | 2009-08-05 | — | — | EP | disclosed |
| CN-1215055-C | Arylsulfonylamino-substituted hydroxamic acid derivatives | NOVARTIS AG (CH) | 2005-08-17 | — | — | CN | disclosed |
| CN-1368958-A | Arylsulfonamido-substituted hydroxamic acid derivatives | NOVARTIS AG (CH) | 2002-09-11 | — | — | CN | disclosed |